Serodus ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Serodus ASA's EGM Approves Merger with Phlogo ApS and Share Capital Increase
Serodus ASA announced that the Company's Extraordinary General Meeting (EGM) unanimously approved the proposed merger with Phlogo ApS. The EGM also passed the resolution to increase the share capital from NOK 15,598,494.60 to NOK 18,198,494.60 by increasing number of shares by issuing 2,000,000 new shares, each with a nominal value of NOK 1.30. The new shares will be issued to the existing shareholders in Phlogo ApS as payment for the merger with Serodus ASA.
Latest Key Developments in Biotechnology
- Tekmira Pharmaceuticals Corp announces proposed public offering of common stock
- La Jolla Pharmaceutical Co reports positive, top-line results from phase 2 clinical trial of gcs-100 in chronic kidney disease
- FDA designates Regado Biosciences Inc's REG1 in PCI as a fast track development program
- Omeros Corporation announces positive OMS721 Data in Serum from patients with aHUS
- Share this
- Digg this